TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11420098

Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg, orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9263613

Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg T.I.D. at meals) plus 1 g oral calcium daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo plus 1 g oral calcium daily
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 149
Study: 8505665

Group type: EXPERIMENTAL
Intervention: Ascorbic acid as tablets (108 mg/d) with iron
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ascorbic acid as tablets (108 mg/d) without iron
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Orange segments or juice
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Raw broccoli
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cooked broccoli
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Synthetic ascorbic acid
Number of subjects: 68
Study: 3442946

Group type: EXPERIMENTAL
Intervention: 40% ethanol administered via nasogastric tube until the 5th postoperative day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no alcohol administration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (alcohol and control)
Number of subjects: 16
Study: 31009598

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Traditional Home Exercise Program (HEP)
Number of subjects: 63
Study: 29233157

Group type: EXPERIMENTAL
Intervention: Brief medical student-delivered cessation intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 25460174

Group type: EXPERIMENTAL
Intervention: Flecainide infusion during provocative testing
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Flecainide infusion
Number of subjects: 59
Study: 23414697

Group type: EXPERIMENTAL
Intervention: Class I graduated elastic compression stockings (18-21 mm Hg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Class II graduated elastic compression stockings (23-32 mm Hg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (both classes)
Number of subjects: 34
Study: 21123667

Group type: EXPERIMENTAL
Intervention: Low-Dye tape (LDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medial arch support (MAS)
Number of subjects: 30
Study: 19901496

Group type: EXPERIMENTAL
Intervention: Self-foot reflexology (performed three times a week for 6 weeks for 40 min at each session)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study: 17110590

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5 mg min/ml) on day 1 plus gemcitabine (1000 mg/m2) on days 1 and 8 for six cycles
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5 mg min/ml) on day 1 plus gemcitabine (1000 mg/m2) for three cycles followed by docetaxel (40 mg/m2) on days 1 and 8 plus gemcitabine (1250 mg/m2) on days 1 and 8 for three cycles (B)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (130 mg/m2) on day 1 plus gemcitabine (1250 mg/m2) on days 1 and 8 for six cycles (C)
Number of subjects: 147
Study: 14764132

Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (asymptomatic microhaematuria)
Number of subjects: 27
Study: 11348533

Group type: EXPERIMENTAL
Intervention: melarsoprol treatment
Number of subjects: 588
Study: 11326873

Group type: EXPERIMENTAL
Intervention: 2SHRZ/3R2H2Z2
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 2SHRZ/3L1H2Z2
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 2S3H3R3Z3/4L1H2Z2
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 2S3H3R3Z3/4L1H2E2
Number of subjects: 366
Study: 8113116

Group type: EXPERIMENTAL
Intervention: External drainage followed by radiation treatment (including intraluminal brachytherapy with Ir-192) in Group II (9 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: External drainage alone in Group I (11 patients)
Number of subjects: 20
Study: 3141643

Group type: EXPERIMENTAL
Intervention: Unweighted polyurethane feeding tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weighted polyurethane feeding tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three tube designs (including weighted and unweighted)
Number of subjects: 0
Study: 29125325

Group type: EXPERIMENTAL
Intervention: DTC television ads for branded prescription drugs
Number of subjects: 68
Study: 28559269

Group type: EXPERIMENTAL
Intervention: Rifampin at 10 mg/kg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampin at 15 mg/kg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampin at 20 mg/kg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Experimental arms (all doses)
Number of subjects: 180
Study: 26424461

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23743467

Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 831

Group type: COMPARATOR
Intervention: 80% oxygen
Number of subjects: 831
Study: 21781337

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted oesophagectomy (transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional open abdominal approach (same procedure as above)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted oesophagectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional open abdominal approach
Number of subjects: 200
Study: 19713070

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.15mg/kg subcutaneously every other day for two weeks
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.15mg/kg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 16454842

Group type: EXPERIMENTAL
Intervention: ePFT
Number of subjects: 12

Group type: COMPARATOR
Intervention: DT
Number of subjects: 12
Study: 15242015

Group type: EXPERIMENTAL
Intervention: Natto intake three times per week (Group 4)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Natto intake once per week (Group 3)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Natto intake once per month (Group 2)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No intake (Group 1)
Number of subjects: 73
Study: 11762555

Group type: EXPERIMENTAL
Intervention: Omapatrilat (25 mg orally or 10 mg intravenously)
Number of subjects: 36
Study: 9236652

Group type: EXPERIMENTAL
Intervention: 500 mg mefenamic acid given one hour before hysteroscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7547097

Group type: EXPERIMENTAL
Intervention: 120 mg tenidap sodium daily for 22 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched placebo daily for 22 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 120 mg tenidap sodium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study: 2141313

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg t.i.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg t.i.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg t.i.d.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 387047

Group type: EXPERIMENTAL
Intervention: Levamisole (30 patients)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (29 patients)
Number of subjects: 59
Study: 31758734

Group type: EXPERIMENTAL
Intervention: Milkshake with resazurin-based solution PrestoBlue (9% v/v)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 10
Study: 31296588

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (800 IU/day for 12 months)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (starch granules)
Number of subjects: 210
Study: 28566743

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 0
Study: 25816296

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 to 100 mg daily added to insulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation of insulin treatment
Number of subjects: 0
Study: 25266426

Group type: EXPERIMENTAL
Intervention: HAART initiation at different CD4% and age thresholds
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: HAART initiation with 'mild' immunosuppression
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: HAART initiation with 'advanced' immunosuppression at age <3 years
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: HAART initiation
Number of subjects: 371
Study: 22312103

Group type: EXPERIMENTAL
Intervention: Three cycles of preoperative chemotherapy with epirubicin 120 mg/m² and ifosfamide 9 g/m² and granulocyte colony-stimulating factor (arm A)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Five cycles of chemotherapy (three preoperative and two postoperative) (arm B)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Comparison of arm A versus arm B
Number of subjects: 328
Study: 20186064

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl iontophoretic transdermal system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia
Number of subjects: 0
Study: 18082873

Group type: EXPERIMENTAL
Intervention: Oral self-reported nonadherence estimates
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral self-reported nonadherence at week 4
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Written self-report of nonadherence at week 12
Number of subjects: 63
Study: 16287370

Group type: EXPERIMENTAL
Intervention: Cycling at 70% of Vo(2)max
Number of subjects: 10

Group type: COMPARATOR
Intervention: Squatting at 70% of 1 repetition maximum
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Squatting
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both exercise modes
Number of subjects: 10
Study: 12383573

Group type: EXPERIMENTAL
Intervention: Heart failure management program delivered by day-hospital (DH)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 234
Study: 10102097

Group type: EXPERIMENTAL
Intervention: Hamstring stretching sessions added to fitness program
Number of subjects: 298

Group type: COMPARATOR
Intervention: Normal basic training
Number of subjects: 298
Study: 8965300

Group type: EXPERIMENTAL
Intervention: Titrated antihypertensive treatment
Number of subjects: 2298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2298
Study: 1998451

Group type: EXPERIMENTAL
Intervention: Baclofen alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stretching regimen with baclofen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretching regimen with placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 30
Study: 6664435

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis (BHD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Acetate dialysis (AHD)
Number of subjects: 11
Study: 31606521

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 108
Study: 28693500

Group type: EXPERIMENTAL
Intervention: Nonblinded group (awareness of accelerometer)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Blinded group (no awareness of accelerometer)
Number of subjects: 80
Study: 25888653

Group type: EXPERIMENTAL
Intervention: Manual therapy and therapeutic patient education
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Manual therapy, therapeutic patient education, and therapeutic exercise protocol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (manual therapy only)
Number of subjects: 45
Study: 23769006

Group type: EXPERIMENTAL
Intervention: Sheltered group (SG)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 21830137

Group type: EXPERIMENTAL
Intervention: Method for extracting BDCPP and DPP metabolites from urine
Number of subjects: 9
Study: 19483252

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (n=13,823)
Number of subjects: 55736

Group type: EXPERIMENTAL
Intervention: Attenders (screening group)
Number of subjects: 55736

Group type: COMPARATOR
Intervention: No screening (control group, n=41,913)
Number of subjects: 55736
Study: 17404830

Group type: EXPERIMENTAL
Intervention: Brief screening instrument for PTSD with a cutoff score of 3 or more
Number of subjects: 6852
Study: 15088044

Group type: EXPERIMENTAL
Intervention: Welch Allyn SureSight (WASS) hand‐held autorefractor
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nidek AR‐820 (NAR)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Retinoscopic refraction (RR)
Number of subjects: 91
Study: 11689583

Group type: EXPERIMENTAL
Intervention: 6% miltefosine solution
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1303534

Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Meperidine (2.2 mg/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (morphine and meperidine)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 29
Study: 4058985

Group type: EXPERIMENTAL
Intervention: Vitamin B6 4.0 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin B6 0.5 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All women (regardless of treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nutritionally relevant doses of vitamin B6
Number of subjects: 20
Study: 30272844

Group type: EXPERIMENTAL
Intervention: 10% carbohydrate solution (10% glucose water; 5, 10, and 15 mL/kg) administered 2 hours before anesthesia
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (strictly restricted to 6-h preoperative fasting)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 1200
Study: 27230269

Group type: EXPERIMENTAL
Intervention: Modified Nutrition Facts Labels (NFLs)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Existing Nutrition Facts Labels (NFLs)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Modified NFLs (specifically relocating the percent daily value component)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Proposed 'added sugars' component
Number of subjects: 155
Study: 25480344

Group type: EXPERIMENTAL
Intervention: Certoparin 8,000 IU aXa per day
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 22869285

Group type: EXPERIMENTAL
Intervention: Dietary intervention (comprehensive dietary modification aimed at lowering insulin levels, including cooking classes and meals at the study center at least twice per week)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (standard diet without intervention)
Number of subjects: 96
Study: 19926964

Group type: EXPERIMENTAL
Intervention: TMC278 25 mg once daily
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: TMC278 75 mg once daily
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: TMC278 150 mg once daily
Number of subjects: 368

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily (control)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: TMC278 (all doses)
Number of subjects: 368
Study: 18432176

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 0
Study: 16444102

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic forms of relaxation therapy (mindfulness-based stress reduction, guided imagery, hypnosis)
Number of subjects: 0
Study: 14578137

Group type: EXPERIMENTAL
Intervention: 600 g of fruits and vegetables
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vitamins and minerals supplement
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 11006063

Group type: EXPERIMENTAL
Intervention: Tailored, self-help dietary intervention (computer-generated personalized letter, motivational phone call, self-help manual, supplementary materials, behavioral feedback, newsletters)
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: Tailored, self-help dietary intervention
Number of subjects: 1459

Group type: COMPARATOR
Intervention: No materials (control group)
Number of subjects: 1459
Study: 8925327

Group type: EXPERIMENTAL
Intervention: Original method of determining rectal compliance using a balloon inflated to 60 ml
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Original method of determining anal canal compliance using a ring-shaped balloon inflated to 12 ml
Number of subjects: 130
Study: 1513728

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (dicloxacillin, cephalexin, or erythromycin orally for seven days)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (local wound care only)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (for full thickness wounds)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (for full thickness wounds)
Number of subjects: 185
Study: 3010383

Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.125 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.25 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.50 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31272957

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid treatment (n=51; range 9-115 months)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Watchful waiting (n=20; range 12-90 months)
Number of subjects: 82
Study: 29482516

Group type: EXPERIMENTAL
Intervention: Educational group intervention by primary healthcare professionals
Number of subjects: 432

Group type: COMPARATOR
Intervention: Routine practice (Control)
Number of subjects: 432
Study: 27299496

Group type: EXPERIMENTAL
Intervention: STA OP! protocol (stepwise multidisciplinary intervention)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (general technical nursing skills, dementia management, and pain management training)
Number of subjects: 288
Study: 23918617

Group type: EXPERIMENTAL
Intervention: +360 kcal/d supplement for 6 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Active women with ExMD
Number of subjects: 8

Group type: COMPARATOR
Intervention: Eumenorrheic active controls (n = 9)
Number of subjects: 8
Study: 22570062

Group type: EXPERIMENTAL
Intervention: Visuospatial task (Tetris)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No-task control condition
Number of subjects: 69
Study: 25928019

Group type: EXPERIMENTAL
Intervention: Structured team briefing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Review of resuscitation guidelines
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 18191355

Group type: EXPERIMENTAL
Intervention: Centella asiatica (250, 500, and 750 mg once daily for 2 months)
Number of subjects: 28
Study: 16874170

Group type: EXPERIMENTAL
Intervention: Pentavalent DTPw-HBV/Hib vaccines with 10, 5, or 2.5 microg of PRP conjugated to tetanus toxoid
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Pentavalent DTPw-HBV/Hib vaccines
Number of subjects: 680
Study: 14513421

Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily) and Placebo
Number of subjects: 293
Study: 10710842

Group type: EXPERIMENTAL
Intervention: Reward (R)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Response Cost (RC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No Contingency (NR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-interest task
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-interest task
Number of subjects: 44
Study: 8938652

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1527255

Group type: EXPERIMENTAL
Intervention: DAR Hygroster (DHS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DAR Hygobac (DHC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pall Ultipor BB50 (PUBC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intersurgical filtatherm (IFT)
Number of subjects: 80
Study: 3835164

Group type: EXPERIMENTAL
Intervention: 80 mg Gentamycin and 600 mg Lincomycin intramuscularly, two hours preoperatively, and every eight hours postoperatively for three days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 80 mg Gentamycin and 600 mg Clindamycin intramuscularly, two hours preoperatively, and every eight hours postoperatively for three days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 80 mg Gentamycin and 500 mg Metronidazole given over 20 minutes, two hours preoperatively, and every eight hours postoperatively for three days
Number of subjects: 90
Study: 31310600

Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil (INS) 0.3 μg/kg with additional doses of 0.15 μg/kg at 10 and 20 minutes if NRS > 3
Number of subjects: 194

Group type: COMPARATOR
Intervention: Intravenous morphine (IVM) 0.1 mg/kg with additional doses of 0.05 mg/kg at 10 and 20 minutes if NRS > 3
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Adverse events in INS group
Number of subjects: 194

Group type: COMPARATOR
Intervention: Adverse events in IVM group
Number of subjects: 194
Study: 29577734

Group type: EXPERIMENTAL
Intervention: Religious history taking by clinicians
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Evaluation of religious histories using the FICA assessment tool
Number of subjects: 66
Study: 27450277

Group type: EXPERIMENTAL
Intervention: DCV 60 mg once daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTG 50 mg once daily for 5 days
Number of subjects: 0